Non-Alcoholic Fatty Liver Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 or older
- People who have been diagnosed with non-alcoholic fatty liver disease (NAFLD) — a condition where excess fat builds up in the liver — confirmed by a doctor, a scan, or a liver tissue sample
- People with NAFLD who also have Type 2 Diabetes may be included
- People who have no liver condition of any kind, including no NAFLD, may be eligible to join as a healthy comparison participant — this would be confirmed using a specialist liver scan called a FibroScan (confirm with trial site)
Who may not be able to join:
- People who are unwilling or unable to give their agreement to take part
- People who have Type 1 Diabetes
- People who have another form of liver disease besides NAFLD, such as viral hepatitis, autoimmune hepatitis, primary sclerosing cholangitis, primary biliary cholangitis, haemochromatosis, sarcoidosis, cystic fibrosis, or sickle cell disease
- People who are taking medications known to affect liver function (except methotrexate)
- People who have an autoimmune disease that, in the trial doctor's opinion, may interfere with immune system testing
- People who are taking medications that suppress the immune system (except methotrexate, a short course of steroid tablets, or steroid inhalers)
- People who are currently pregnant
- People who have had a major organ transplant (corneal or hair transplants are not excluded)
- People who regularly drink more than 14 units of alcohol per week (for women) or more than 21 units per week (for men)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: William Alazawi, MD Phd, Queen Mary University of London
Phone: +442078822308
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Impact of weight loss surgery upon Non-alcoholic steatohepatitis
Can't join this trial?
Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.